日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma

开发用于诊断黑色素瘤纳武利尤单抗治疗的程序性死亡受体1配体1免疫组化检测方法

Phillips, Therese; Millett, Molly M; Zhang, Xiaoling; Jansson, Malinka; Cleveland, Rachel; Simmons, Pauline; Cherryholmes, Gregory; Carnahan, Josette; William, Josette; Spaulding, Betsy; Satnick, Ilana R; Inzunza, H David; Taylor, Clive; Cogswell, John; Novotny, James; Oroudjev, Emin; Winther, Henrik

An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.

Dako 28-8 PharmDx 检测与 E1L3N 实验室开发的检测在程序性死亡配体 1 的免疫组织化学检测中的分析比较

Cogswell John, Inzunza H David, Wu Qiuyan, Feder John N, Mintier Gabe, Novotny James, Cardona Diana M

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma

纳武利尤单抗联合疫苗辅助治疗切除的高危转移性黑色素瘤的安全性、相关标志物和临床结果

Gibney, Geoffrey T; Kudchadkar, Ragini R; DeConti, Ronald C; Thebeau, Melissa S; Czupryn, Maria P; Tetteh, Leticia; Eysmans, Cabell; Richards, Allison; Schell, Michael J; Fisher, Kate J; Horak, Christine E; Inzunza, H David; Yu, Bin; Martinez, Alberto J; Younos, Ibrahim; Weber, Jeffrey S

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

纳武利尤单抗联合疫苗治疗对伊匹木单抗耐药或未接受过伊匹木单抗治疗的黑色素瘤的安全性、有效性和生物标志物

Weber, Jeffrey S; Kudchadkar, Ragini Reiney; Yu, Bin; Gallenstein, Donna; Horak, Christine E; Inzunza, H David; Zhao, Xiuhua; Martinez, Alberto J; Wang, Wenshi; Gibney, Geoffrey; Kroeger, Jodi; Eysmans, Cabell; Sarnaik, Amod A; Chen, Y Ann